InVivoMAb anti-human GPC3

Ma L, Heinrich S, Wang L, et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022,13(1):7533. doi: 10.1038/s41467-022-35291-5

Liu X, Gao F, Jiang L, et al. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. J Transl Med. 2020,18(1):295. doi: 10.1186/s12967-020-02462-1

Li N, Spetz MR, Ho M. The Role of Glypicans in Cancer Progression and Therapy. J Histochem Cytochem. 2020,68(12):841-862. doi: 10.1369/0022155420933709

Li D, Li N, Zhang YF, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology. 2020,158(8):2250-2265.e20. doi: 10.1053/j.gastro.2020.02.011

Li N, Wei L, Liu X, et al. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice. Hepatology. 2019,70(4):1231-1245. doi: 10.1002/hep.30646

Chahoud J, Zhang M, Pisters LL, et al. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018,16(5):325-327. doi: 10.1016/j.clgc.2018.05.004

Li W, Guo L, Rathi P, et al. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017,28(5):437-448. doi: 10.1089/hum.2016.025

Gao W, Kim H, Ho M. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One. 2015,10(9):e0137664. doi: 10.1371/journal.pone.0137664

Hanaoka H, Nagaya T, Sato K, et al. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm. 2015,12(6):2151-7. doi: 10.1021/acs.molpharmaceut.5b00132

Hanaoka H, Nakajima T, Sato K, et al. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine (Lond). 2015,10(7):1139-47. doi: 10.2217/nnm.14.194